PR Newswire
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
📈
AI Sentiment
Highly Positive
8/10
- Home
- WHWK
as of 12-04-2025 3:40pm EST
$2.55
+$0.30
+13.62%
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Chart Type:
Time Range:
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | MORRISTOWN |
| Market Cap: | 95.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 203.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.39 - $3.81 | Next Earning Date: | 11-06-2025 |
| Revenue: | $14,384,000 | Revenue Growth: | -42.63% |
| Revenue Growth (this year): | -72.04% | Revenue Growth (next year): | N/A |
AI-Powered WHWK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 83.33%
83.33%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Whitehawk Therapeutics Inc. Common Stock News
WHWK Breaking Stock News: Dive into WHWK Ticker-Specific Updates for Smart Investing
Compare WHWK vs Leading Stocks
See how WHWK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "WHWK Whitehawk Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.